PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27268079-1 2016 BACKGROUND: It has been shown that epidermal growth factor receptor (EGFR) mutation status is associated with 5-fluorouracil (5-FU) sensitivity in non-small-cell lung cancer (NSCLC). Fluorouracil 110-124 epidermal growth factor receptor Homo sapiens 35-67 27878272-0 2017 miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer. Fluorouracil 16-20 epidermal growth factor receptor Homo sapiens 57-61 27878272-12 2017 Our findings suggest that miR-20b reduces 5-FU resistance to induce apoptosis in vitro by suppressing ADAM9/EGFR in CC cells. Fluorouracil 42-46 epidermal growth factor receptor Homo sapiens 108-112 27833077-0 2016 Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy. Fluorouracil 67-79 epidermal growth factor receptor Homo sapiens 5-9 27833077-9 2016 Together, our data suggest that EGFR monoclonal antibody may sensitize CSC-like CRC cells to 5-FU-induced apoptosis by affecting autophagy. Fluorouracil 93-97 epidermal growth factor receptor Homo sapiens 32-36 27602148-6 2016 It was observed that RNAi-mediated downregulation of EGFR or MRP2 increased the sensitivity to 5-FU and cisplatin in OC2 cells. Fluorouracil 95-99 epidermal growth factor receptor Homo sapiens 53-57 27602148-7 2016 Downregulation of EGFR resulted in significant suppression of OC2 tumor growth following 5-FU administration. Fluorouracil 89-93 epidermal growth factor receptor Homo sapiens 18-22 27340349-2 2016 In addition, the combined strategies of administering EGFR mAbs and traditional cytotoxic agents, such as 5-fluorouracil, oxaliplatin and irinotecan, have resulted in a more complicated management of CRC treatment-related side effects compared with EGFR mAb monotherapy. Fluorouracil 106-120 epidermal growth factor receptor Homo sapiens 54-58 27340349-2 2016 In addition, the combined strategies of administering EGFR mAbs and traditional cytotoxic agents, such as 5-fluorouracil, oxaliplatin and irinotecan, have resulted in a more complicated management of CRC treatment-related side effects compared with EGFR mAb monotherapy. Fluorouracil 106-120 epidermal growth factor receptor Homo sapiens 249-253 27091477-0 2016 Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report. Fluorouracil 48-60 epidermal growth factor receptor Homo sapiens 0-32 27268079-1 2016 BACKGROUND: It has been shown that epidermal growth factor receptor (EGFR) mutation status is associated with 5-fluorouracil (5-FU) sensitivity in non-small-cell lung cancer (NSCLC). Fluorouracil 110-124 epidermal growth factor receptor Homo sapiens 69-73 27268079-1 2016 BACKGROUND: It has been shown that epidermal growth factor receptor (EGFR) mutation status is associated with 5-fluorouracil (5-FU) sensitivity in non-small-cell lung cancer (NSCLC). Fluorouracil 126-130 epidermal growth factor receptor Homo sapiens 35-67 27268079-1 2016 BACKGROUND: It has been shown that epidermal growth factor receptor (EGFR) mutation status is associated with 5-fluorouracil (5-FU) sensitivity in non-small-cell lung cancer (NSCLC). Fluorouracil 126-130 epidermal growth factor receptor Homo sapiens 69-73 26505786-9 2016 In addition, curcumin exposure along with 5-FU or DOX inhibited cell proliferation through the downregulation of EGFR-ERK1/2 signaling molecules. Fluorouracil 42-46 epidermal growth factor receptor Homo sapiens 113-117 27610130-12 2016 This analysis suggests a prognostic impact of both ERBB1 and MKi67 mRNA expression in LARC patients treated with capecitabine or fluorouracil-based chemoradiotherapy. Fluorouracil 129-141 epidermal growth factor receptor Homo sapiens 51-56 25750344-6 2015 CONCLUSION: Our data suggest that patients with adenocarcinoma harboring EGFR gene mutations may be susceptible to 5-FU. Fluorouracil 115-119 epidermal growth factor receptor Homo sapiens 73-77 26088456-10 2015 CONCLUSIONS: The choice of an anti-EGFR MoAb as first-line biologic is a valid option in RAS wild-type patients candidate to a doublet with infusional 5-FU. Fluorouracil 151-155 epidermal growth factor receptor Homo sapiens 35-39 26275292-12 2015 Further analyses of oxaliplatin+EGFR-I trials showed greater efficacy with infusional 5FU regimens (PFS HR 0.82, 95% CI 0.72-0.94) compared to capecitabine (HR 1.09; 95% CI 0.91-1.30) and bolus 5FU (HR 1.07; 95% CI 0.79-1.45); subgroup interaction was present with I2 = 72%, p = 0.03. Fluorouracil 86-89 epidermal growth factor receptor Homo sapiens 32-36 25750344-5 2015 RESULTS: In patients with adenocarcinoma, tumors with EGFR gene mutations were significantly more sensitive to 5-fluorouracil (5-FU) than tumors without EGFR gene mutations (p<0.0149). Fluorouracil 111-125 epidermal growth factor receptor Homo sapiens 54-58 25750344-5 2015 RESULTS: In patients with adenocarcinoma, tumors with EGFR gene mutations were significantly more sensitive to 5-fluorouracil (5-FU) than tumors without EGFR gene mutations (p<0.0149). Fluorouracil 127-131 epidermal growth factor receptor Homo sapiens 54-58 25573239-9 2015 We propose that the EGFR dephosphorylation induced by VNR is related to cell growth inhibitory activity of VNR, and that this is one of the mechanisms of the synergistic effect of VNR + 5-FU in EGFR-mutated lung cancer cells. Fluorouracil 186-190 epidermal growth factor receptor Homo sapiens 20-24 25573239-9 2015 We propose that the EGFR dephosphorylation induced by VNR is related to cell growth inhibitory activity of VNR, and that this is one of the mechanisms of the synergistic effect of VNR + 5-FU in EGFR-mutated lung cancer cells. Fluorouracil 186-190 epidermal growth factor receptor Homo sapiens 194-198 24591842-6 2014 Exposure to celecoxib (21.8 mumol/L) plus 5-fluorouracil (8.1 x 10(-3) g/L) or sorafenib (4.4 mumol/L) increased apoptosis but exerted no effect on COX2, phosphorylated epidermal growth-factor receptor (p-EGFR) and phosphorylated (p)-AKT expression. Fluorouracil 42-56 epidermal growth factor receptor Homo sapiens 169-201 24405586-0 2014 High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil. Fluorouracil 208-222 epidermal growth factor receptor Homo sapiens 106-138 24405586-1 2014 BACKGROUND: It has been shown that 5-fluorouracil (5-FU) sensitivity in patients with non-small-cell lung cancer (NSCLC) is associated with epidermal growth factor receptor (EGFR) mutation status. Fluorouracil 35-49 epidermal growth factor receptor Homo sapiens 140-172 24405586-1 2014 BACKGROUND: It has been shown that 5-fluorouracil (5-FU) sensitivity in patients with non-small-cell lung cancer (NSCLC) is associated with epidermal growth factor receptor (EGFR) mutation status. Fluorouracil 35-49 epidermal growth factor receptor Homo sapiens 174-178 24405586-1 2014 BACKGROUND: It has been shown that 5-fluorouracil (5-FU) sensitivity in patients with non-small-cell lung cancer (NSCLC) is associated with epidermal growth factor receptor (EGFR) mutation status. Fluorouracil 51-55 epidermal growth factor receptor Homo sapiens 140-172 24405586-1 2014 BACKGROUND: It has been shown that 5-fluorouracil (5-FU) sensitivity in patients with non-small-cell lung cancer (NSCLC) is associated with epidermal growth factor receptor (EGFR) mutation status. Fluorouracil 51-55 epidermal growth factor receptor Homo sapiens 174-178 24351824-0 2013 Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells. Fluorouracil 30-44 epidermal growth factor receptor Homo sapiens 49-53 24351824-7 2013 These results suggest that Cbl-b enhances sensitivity to 5-FU via EGFR- and mitochondria-mediated pathways in gastric cancer cells. Fluorouracil 57-61 epidermal growth factor receptor Homo sapiens 66-70 23800895-0 2013 Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. Fluorouracil 148-162 epidermal growth factor receptor Homo sapiens 46-78 23800895-0 2013 Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. Fluorouracil 148-162 epidermal growth factor receptor Homo sapiens 80-84 23800895-1 2013 PURPOSE: This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy. Fluorouracil 203-217 epidermal growth factor receptor Homo sapiens 78-110 23800895-1 2013 PURPOSE: This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy. Fluorouracil 203-217 epidermal growth factor receptor Homo sapiens 112-116 23800895-8 2013 CONCLUSIONS: EGFR polymorphisms can serve as prognostic predictors for CRC patients receiving 5-FU-based chemotherapy. Fluorouracil 94-98 epidermal growth factor receptor Homo sapiens 13-17 22293713-9 2012 The potentiation effect of combined treatment was associated with downregulation of EGFR and HER2 signaling pathways because data from western blot analysis showed that lapatinib in combination with 5-Fu markedly reduced the phosphorylation of EGFR and HER2, and inhibited the activation of downstream signaling molecules, such as AKT and ERK. Fluorouracil 223-227 epidermal growth factor receptor Homo sapiens 96-100 24221219-3 2013 Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Fluorouracil 249-253 epidermal growth factor receptor Homo sapiens 34-38 23085230-6 2012 Here, we adopted a prodrug system that uses 5-fluorocytosine (5-FC) and human EGF (hEGF) fused with yeast cytosine deaminase (Fcy) to target EGFR-overexpressing cancer cells and to convert 5-FC to a significantly more toxic chemotherapeutic, 5-fluorouracil (5-FU). Fluorouracil 242-256 epidermal growth factor receptor Homo sapiens 141-145 23085230-6 2012 Here, we adopted a prodrug system that uses 5-fluorocytosine (5-FC) and human EGF (hEGF) fused with yeast cytosine deaminase (Fcy) to target EGFR-overexpressing cancer cells and to convert 5-FC to a significantly more toxic chemotherapeutic, 5-fluorouracil (5-FU). Fluorouracil 258-262 epidermal growth factor receptor Homo sapiens 141-145 23822592-2 2013 This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs. Fluorouracil 282-296 epidermal growth factor receptor Homo sapiens 102-134 23822592-2 2013 This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs. Fluorouracil 282-296 epidermal growth factor receptor Homo sapiens 136-140 23822592-2 2013 This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs. Fluorouracil 298-302 epidermal growth factor receptor Homo sapiens 102-134 23822592-2 2013 This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs. Fluorouracil 298-302 epidermal growth factor receptor Homo sapiens 136-140 23755922-1 2013 PURPOSE: To investigate the prognostic value of epidermal growth factor receptor (EGFR) expression in pretreatment tumor biopsy specimens of patients with anal cancer treated with concurrent 5-fluorouracil and mitomycin C-based chemoradiation therapy (CRT). Fluorouracil 191-205 epidermal growth factor receptor Homo sapiens 48-80 23755922-1 2013 PURPOSE: To investigate the prognostic value of epidermal growth factor receptor (EGFR) expression in pretreatment tumor biopsy specimens of patients with anal cancer treated with concurrent 5-fluorouracil and mitomycin C-based chemoradiation therapy (CRT). Fluorouracil 191-205 epidermal growth factor receptor Homo sapiens 82-86 23708506-8 2013 Lapatinib in combination with 5-FU had more potent antitumor effects in the primary ESCC xenograft model, and markedly reduced the phosphorylation of EGFR and HER2, compared with lapatinib alone or in combination with oxaliplatin. Fluorouracil 30-34 epidermal growth factor receptor Homo sapiens 150-154 22052826-4 2013 Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), significantly improved median survival in combination with platinum/5-FU compared with chemotherapy alone, establishing it as a new standard for patients with recurrent or metastatic disease. Fluorouracil 150-154 epidermal growth factor receptor Homo sapiens 75-79 22252310-5 2012 The EGFR-targeted monoclonal antibody cetuximab is approved for the treatment of locally advanced SCCHN in combination with radiotherapy, for first-line treatment of recurrent or metastatic SCCHN in combination with platinum-based chemotherapy and 5-fluorouracil, and for recurrent or metastatic SCCHN following progression with platinum-based chemotherapy. Fluorouracil 248-262 epidermal growth factor receptor Homo sapiens 4-8 22192364-3 2012 Anti-EGFR agents can be added to first-line FOLFIRI (5-fluorouracil, leucovorin [folinic acid], irinotecan) or FOLFOX (5-fluorouracil, leucovorin [folinic acid], oxaliplatin) in patients whose tumors express wild-type KRAS. Fluorouracil 53-67 epidermal growth factor receptor Homo sapiens 5-9 22192364-3 2012 Anti-EGFR agents can be added to first-line FOLFIRI (5-fluorouracil, leucovorin [folinic acid], irinotecan) or FOLFOX (5-fluorouracil, leucovorin [folinic acid], oxaliplatin) in patients whose tumors express wild-type KRAS. Fluorouracil 119-133 epidermal growth factor receptor Homo sapiens 5-9 22293713-9 2012 The potentiation effect of combined treatment was associated with downregulation of EGFR and HER2 signaling pathways because data from western blot analysis showed that lapatinib in combination with 5-Fu markedly reduced the phosphorylation of EGFR and HER2, and inhibited the activation of downstream signaling molecules, such as AKT and ERK. Fluorouracil 223-227 epidermal growth factor receptor Homo sapiens 280-284 22139134-9 2012 The combination of 5FU and cetuximab synergistically inhibited cell proliferation and exhibited an enhanced proapoptotic effect in GC cells with EGFR overexpression. Fluorouracil 19-22 epidermal growth factor receptor Homo sapiens 145-149 20943624-8 2010 After decades without real progress, a recent European randomized trial showed that adding cetuximab, the first clinically available EGFR-directed monoclonal antibody, to a standard chemotherapy regimen (platinum/5-fluorouracil) leads to an important survival benefit and this, with support of an additional smaller study in the US, has changed practice. Fluorouracil 213-227 epidermal growth factor receptor Homo sapiens 133-137 21947696-0 2012 Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Fluorouracil 175-187 epidermal growth factor receptor Homo sapiens 79-111 21710497-5 2011 Ad-FZ33 expressing uracil phosphoribosyl transferase (UPRT), an enzyme which greatly enhances the toxicity of 5-fluorouracil (FU), combined with antibodies against EpCAM or EGFR, remarkably enhanced the sensitivity of biliary cancer cells to 5-FU. Fluorouracil 242-246 epidermal growth factor receptor Homo sapiens 173-177 20346742-1 2010 We document an EGFR mutation in a patient with papillary renal cell cancer with a history of multiple therapies, including interferon-alpha, interleukin-2, 5-fluorouracil, and interferon-alpha together with 13-cis-retinoic acid, to which floxuridine was later added, and thalidomide maintenance therapy for six years. Fluorouracil 156-170 epidermal growth factor receptor Homo sapiens 15-19 19259093-0 2009 Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Fluorouracil 115-129 epidermal growth factor receptor Homo sapiens 192-196 19217205-6 2009 Furthermore, 5-FU has significantly lower inhibition effect on Huh7-EGFRvIII cells then on both Huh-7 and Huh7-EGFR cells in vitro and in vivo. Fluorouracil 13-17 epidermal growth factor receptor Homo sapiens 68-72 19366444-1 2009 BACKGROUND: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer. Fluorouracil 224-238 epidermal growth factor receptor Homo sapiens 116-120 19366444-1 2009 BACKGROUND: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer. Fluorouracil 240-244 epidermal growth factor receptor Homo sapiens 82-114 19366444-1 2009 BACKGROUND: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer. Fluorouracil 240-244 epidermal growth factor receptor Homo sapiens 116-120 20399639-6 2010 These drugs were able to up-regulate EGFR expression on the surface of all the colon cancer cell lines with a maximal effect observed few hours after the exposure to GILF regimen (Gem, Iri, Levofolinic acid and 5-FU). Fluorouracil 211-215 epidermal growth factor receptor Homo sapiens 37-41 20180626-13 2010 DISCUSSION: Potential reasons for the disappointing results of EGFR inhibition with fluoropyrimidine-based preoperative chemoradiation include a less critical role of repopulation in rectal adenocarcinoma using a non-curative radiation dose; or antagonistic effects on 5FU-based chemoradiation and oxaliplatin, if some cells arrest in G1 or G2-M and fail to pass through S phase. Fluorouracil 269-272 epidermal growth factor receptor Homo sapiens 63-67 16984384-0 2006 Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Fluorouracil 105-119 epidermal growth factor receptor Homo sapiens 32-64 18794807-7 2008 Furthermore, the combination of 5-FU+PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway. Fluorouracil 32-36 epidermal growth factor receptor Homo sapiens 82-114 18794807-7 2008 Furthermore, the combination of 5-FU+PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway. Fluorouracil 32-36 epidermal growth factor receptor Homo sapiens 116-120 18794807-7 2008 Furthermore, the combination of 5-FU+PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway. Fluorouracil 55-59 epidermal growth factor receptor Homo sapiens 82-114 18794807-7 2008 Furthermore, the combination of 5-FU+PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway. Fluorouracil 55-59 epidermal growth factor receptor Homo sapiens 116-120 18794807-10 2008 A potential mechanism of action of Src kinase inhibitors on 5-FU chemosensitivity might be linked to the inhibition of 5-FU-induced EGFR-AKT activation. Fluorouracil 60-64 epidermal growth factor receptor Homo sapiens 132-136 18794807-10 2008 A potential mechanism of action of Src kinase inhibitors on 5-FU chemosensitivity might be linked to the inhibition of 5-FU-induced EGFR-AKT activation. Fluorouracil 119-123 epidermal growth factor receptor Homo sapiens 132-136 19095777-0 2009 Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Fluorouracil 119-123 epidermal growth factor receptor Homo sapiens 0-32 19095777-10 2009 CONCLUSIONS: In pts with LARC, EGFR GCN is predictive of high TRG to cetuximab plus 5-FU radiotherapy. Fluorouracil 84-88 epidermal growth factor receptor Homo sapiens 31-35 18497992-1 2008 To understand one of the mechanisms of resistance to chemoradiation in colon cancer cells, we investigated whether 5-fluorouracil (5-FU) mediated the expression of epidermal growth factor receptor (EGFR) and modified repair of radiation-induced DNA damage, especially in a p53 independent pathway. Fluorouracil 115-129 epidermal growth factor receptor Homo sapiens 164-196 18497992-1 2008 To understand one of the mechanisms of resistance to chemoradiation in colon cancer cells, we investigated whether 5-fluorouracil (5-FU) mediated the expression of epidermal growth factor receptor (EGFR) and modified repair of radiation-induced DNA damage, especially in a p53 independent pathway. Fluorouracil 115-129 epidermal growth factor receptor Homo sapiens 198-202 18497992-1 2008 To understand one of the mechanisms of resistance to chemoradiation in colon cancer cells, we investigated whether 5-fluorouracil (5-FU) mediated the expression of epidermal growth factor receptor (EGFR) and modified repair of radiation-induced DNA damage, especially in a p53 independent pathway. Fluorouracil 131-135 epidermal growth factor receptor Homo sapiens 164-196 18497992-1 2008 To understand one of the mechanisms of resistance to chemoradiation in colon cancer cells, we investigated whether 5-fluorouracil (5-FU) mediated the expression of epidermal growth factor receptor (EGFR) and modified repair of radiation-induced DNA damage, especially in a p53 independent pathway. Fluorouracil 131-135 epidermal growth factor receptor Homo sapiens 198-202 18497992-6 2008 5-FU-induced activation of EGFR followed by radiation in SW480 cells resulted in up-regulation of ERCC1. Fluorouracil 0-4 epidermal growth factor receptor Homo sapiens 27-31 18497992-7 2008 In contrast, 5-FU-induced degradation of EGFR followed by radiation in the other radiosensitive cell lines resulted in down-regulation of ERCC1. Fluorouracil 13-17 epidermal growth factor receptor Homo sapiens 41-45 18497992-8 2008 This suggested a complementary interaction between EGFR and ERCC1, and that 5-FU-induced EGFR activation conferred protection against radiation, through activation of DNA repair. Fluorouracil 76-80 epidermal growth factor receptor Homo sapiens 89-93 18497992-9 2008 Interaction of EGFR and ERCC1 might correlate with radiation-induced DNA damage when p53 mutant colon cancer cell lines are exposed to 5-FU followed by radiation. Fluorouracil 135-139 epidermal growth factor receptor Homo sapiens 15-19 21136888-1 2008 The monoclonal antibody cetuximab directed against the epidermal growth factor receptor (EGFR) is an attractive agent for targeted therapy in advanced colorectal cancer (CRC), especially when combined with 5-fluorouracil (5-FU)-based chemotherapy. Fluorouracil 222-226 epidermal growth factor receptor Homo sapiens 55-87 21136888-1 2008 The monoclonal antibody cetuximab directed against the epidermal growth factor receptor (EGFR) is an attractive agent for targeted therapy in advanced colorectal cancer (CRC), especially when combined with 5-fluorouracil (5-FU)-based chemotherapy. Fluorouracil 222-226 epidermal growth factor receptor Homo sapiens 89-93 21136888-7 2008 Combined treatment with cetuximab and 5-FU revealed a synergistic anti-tumor response that is closely correlated with functional activity of EGFR/mitogen-activated protein kinase (MAPK) pathway. Fluorouracil 38-42 epidermal growth factor receptor Homo sapiens 141-145 21136888-9 2008 We demonstrated that only EGFR expression with high functional activity of EGFR/MAPK pathway is important for the synergistic effects between cetuximab and 5-FU in the investigated cell lines. Fluorouracil 156-160 epidermal growth factor receptor Homo sapiens 26-30 21136888-9 2008 We demonstrated that only EGFR expression with high functional activity of EGFR/MAPK pathway is important for the synergistic effects between cetuximab and 5-FU in the investigated cell lines. Fluorouracil 156-160 epidermal growth factor receptor Homo sapiens 75-79 17918158-0 2008 Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Fluorouracil 33-47 epidermal growth factor receptor Homo sapiens 131-135 17511782-4 2007 Using these methods, we show that EGFR kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity. Fluorouracil 101-115 epidermal growth factor receptor Homo sapiens 34-38 17511782-4 2007 Using these methods, we show that EGFR kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity. Fluorouracil 101-115 epidermal growth factor receptor Homo sapiens 151-155 17761979-5 2007 The antiproliferative effect of fluorouracil (FU) on adenocarcinoma cell lines with EGFR wild-type or mutant type status was examined by measuring the inhibitory concentrations at 50% (IC(50)s). Fluorouracil 32-44 epidermal growth factor receptor Homo sapiens 84-88 17169374-0 2007 Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. Fluorouracil 110-124 epidermal growth factor receptor Homo sapiens 47-51 17169374-11 2007 CONCLUSIONS: Both pU6-EGFR-shRNA-1 and pU6-EGFR-shRNA-2 are capable of suppressing EGFR expression of the LoVo cell and can promote apoptosis and increase the cell toxicity of 5-FU. Fluorouracil 176-180 epidermal growth factor receptor Homo sapiens 22-26 17169374-11 2007 CONCLUSIONS: Both pU6-EGFR-shRNA-1 and pU6-EGFR-shRNA-2 are capable of suppressing EGFR expression of the LoVo cell and can promote apoptosis and increase the cell toxicity of 5-FU. Fluorouracil 176-180 epidermal growth factor receptor Homo sapiens 43-47 17169374-11 2007 CONCLUSIONS: Both pU6-EGFR-shRNA-1 and pU6-EGFR-shRNA-2 are capable of suppressing EGFR expression of the LoVo cell and can promote apoptosis and increase the cell toxicity of 5-FU. Fluorouracil 176-180 epidermal growth factor receptor Homo sapiens 43-47 16984384-7 2006 Treatment with EGFR siRNA in combination with cisplatin, 5-FU and docetaxel enhanced chemosensitivity with a significant increase in apoptosis. Fluorouracil 57-61 epidermal growth factor receptor Homo sapiens 15-19 16984384-9 2006 These cumulative results suggest that EGFR siRNA combined with cisplatin, 5-FU and docetaxel may be a feasible strategy to enhance the effects of chemotherapy in patients with HNSCC. Fluorouracil 74-78 epidermal growth factor receptor Homo sapiens 38-42 16303861-0 2006 Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Fluorouracil 25-39 epidermal growth factor receptor Homo sapiens 121-153 16794239-3 2006 DESIGN: This review summarizes current clinical data for EGFR-TKIs as monotherapy or in combination with 5-fluorouracil/leucovorin, irinotecan, or oxaliplatin, focusing on the rapidly developing area of colorectal, gastroesophageal, and pancreatic cancers. Fluorouracil 105-119 epidermal growth factor receptor Homo sapiens 57-61 16836928-0 2006 [Double sites short hairpin RNAs targeting epidermal growth factor receptor to promote colon cancer cells apoptosis and enhance 5-fluorouracil chemotherapy effect]. Fluorouracil 128-142 epidermal growth factor receptor Homo sapiens 43-75 16836928-8 2006 CONCLUSIONS: Both pU6-EGFR-shRNA-1 and pU6-EGFR-shRNA-2 were capable of suppressing EGFR expression of LoVo cells, and therefore promoting apoptosis and increasing the cell toxicity of 5-FU. Fluorouracil 185-189 epidermal growth factor receptor Homo sapiens 22-26 16836928-8 2006 CONCLUSIONS: Both pU6-EGFR-shRNA-1 and pU6-EGFR-shRNA-2 were capable of suppressing EGFR expression of LoVo cells, and therefore promoting apoptosis and increasing the cell toxicity of 5-FU. Fluorouracil 185-189 epidermal growth factor receptor Homo sapiens 43-47 16836928-8 2006 CONCLUSIONS: Both pU6-EGFR-shRNA-1 and pU6-EGFR-shRNA-2 were capable of suppressing EGFR expression of LoVo cells, and therefore promoting apoptosis and increasing the cell toxicity of 5-FU. Fluorouracil 185-189 epidermal growth factor receptor Homo sapiens 43-47 16563096-3 2006 For example: 5-fluorouracil-derived agents would be used for tumors with a low expression of thymidylate synthase; gefitinib and erlotinib for tumors with epidermal growth factor receptor (EGFR) mutations or increased EGFR gene copy numbers; cisplatin and carboplatin for tumors with a low expression of excision repair cross complementing-1; and gemcitabine for tumors with a low expression of ribonucleotide reductase. Fluorouracil 13-27 epidermal growth factor receptor Homo sapiens 189-193 16563096-3 2006 For example: 5-fluorouracil-derived agents would be used for tumors with a low expression of thymidylate synthase; gefitinib and erlotinib for tumors with epidermal growth factor receptor (EGFR) mutations or increased EGFR gene copy numbers; cisplatin and carboplatin for tumors with a low expression of excision repair cross complementing-1; and gemcitabine for tumors with a low expression of ribonucleotide reductase. Fluorouracil 13-27 epidermal growth factor receptor Homo sapiens 218-222 8758793-9 1996 Transfection with pDOR-erbB-neo rendered the cells significantly, more sensitive to chemotherapeutic drugs (5-fluorouracil, cisplatinum) than the parental cells. Fluorouracil 108-122 epidermal growth factor receptor Homo sapiens 23-27 12967482-1 2003 We previously demonstrated that epidermal growth factor (EGF) induces a decrease in dihydropyrimidine dehydrogenase (DPD), which is the first and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), in EGF receptor (EGFR)-positive human SKG-IIIb uterine cervical carcinoma cells, and thereby increased the sensitivity of the cells to 5-FU. Fluorouracil 188-202 epidermal growth factor receptor Homo sapiens 214-226 12967482-1 2003 We previously demonstrated that epidermal growth factor (EGF) induces a decrease in dihydropyrimidine dehydrogenase (DPD), which is the first and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), in EGF receptor (EGFR)-positive human SKG-IIIb uterine cervical carcinoma cells, and thereby increased the sensitivity of the cells to 5-FU. Fluorouracil 188-202 epidermal growth factor receptor Homo sapiens 228-232 12967482-1 2003 We previously demonstrated that epidermal growth factor (EGF) induces a decrease in dihydropyrimidine dehydrogenase (DPD), which is the first and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), in EGF receptor (EGFR)-positive human SKG-IIIb uterine cervical carcinoma cells, and thereby increased the sensitivity of the cells to 5-FU. Fluorouracil 204-208 epidermal growth factor receptor Homo sapiens 214-226 12967482-1 2003 We previously demonstrated that epidermal growth factor (EGF) induces a decrease in dihydropyrimidine dehydrogenase (DPD), which is the first and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), in EGF receptor (EGFR)-positive human SKG-IIIb uterine cervical carcinoma cells, and thereby increased the sensitivity of the cells to 5-FU. Fluorouracil 204-208 epidermal growth factor receptor Homo sapiens 228-232 12967482-1 2003 We previously demonstrated that epidermal growth factor (EGF) induces a decrease in dihydropyrimidine dehydrogenase (DPD), which is the first and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), in EGF receptor (EGFR)-positive human SKG-IIIb uterine cervical carcinoma cells, and thereby increased the sensitivity of the cells to 5-FU. Fluorouracil 346-350 epidermal growth factor receptor Homo sapiens 214-226 12967482-1 2003 We previously demonstrated that epidermal growth factor (EGF) induces a decrease in dihydropyrimidine dehydrogenase (DPD), which is the first and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), in EGF receptor (EGFR)-positive human SKG-IIIb uterine cervical carcinoma cells, and thereby increased the sensitivity of the cells to 5-FU. Fluorouracil 346-350 epidermal growth factor receptor Homo sapiens 228-232 12888834-3 2003 We have previously demonstrated a synergistic interaction between ZD1839 and cisplatin/5-fluorouracil (5FU) in CAL33, a human head and neck cancer cell line that markedly expresses EGFR. Fluorouracil 87-101 epidermal growth factor receptor Homo sapiens 181-185 12888834-3 2003 We have previously demonstrated a synergistic interaction between ZD1839 and cisplatin/5-fluorouracil (5FU) in CAL33, a human head and neck cancer cell line that markedly expresses EGFR. Fluorouracil 103-106 epidermal growth factor receptor Homo sapiens 181-185 11927016-8 2002 The YCU-H891 cells, in which the epidermal growth factor receptor (EGFR)-signal transducer and activator of transcription 3 (Stat3) pathway is constitutively activated, were more resistant to treatments with ATRA, 5-FU and the combination of both agents than YCU-N861 cells. Fluorouracil 214-218 epidermal growth factor receptor Homo sapiens 33-65 11927016-8 2002 The YCU-H891 cells, in which the epidermal growth factor receptor (EGFR)-signal transducer and activator of transcription 3 (Stat3) pathway is constitutively activated, were more resistant to treatments with ATRA, 5-FU and the combination of both agents than YCU-N861 cells. Fluorouracil 214-218 epidermal growth factor receptor Homo sapiens 67-71 16243822-9 2005 In contrast to oxaliplatin, 5-FU treatment increased EGFR phosphorylation in all cell lines and this correlated with synergistic decreases in cell viability when 5-FU was combined with gefitinib. Fluorouracil 28-32 epidermal growth factor receptor Homo sapiens 53-57 16243822-9 2005 In contrast to oxaliplatin, 5-FU treatment increased EGFR phosphorylation in all cell lines and this correlated with synergistic decreases in cell viability when 5-FU was combined with gefitinib. Fluorouracil 162-166 epidermal growth factor receptor Homo sapiens 53-57 10206306-0 1999 A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Fluorouracil 213-227 epidermal growth factor receptor Homo sapiens 45-77 8054813-9 1994 These data indicate that EGF may be a potent agent as a biological response modifier for 5-FU against the tumors which express the EGF/EGFR autocrine mechanism, and that the TSG6 cell line is useful in furthering our understanding of the interaction between anticancer drugs and EGF. Fluorouracil 89-93 epidermal growth factor receptor Homo sapiens 135-139 33033330-8 2020 This study demonstrated that the VLNP can be used to deliver chemically modified 5-FU derivatives to cancer cells overexpressing EGFR, expanding the applications of the VLNP in targeted delivery of chemotherapeutic agents to cancer cells overexpressing this transmembrane receptor. Fluorouracil 81-85 epidermal growth factor receptor Homo sapiens 129-133 34951582-7 2022 EGFR and KRAS gene expression analysis under the influence of PFNPs, FGNPs, PFGNPs, and 5-FU was studied and observed maximum potency for PFNPs. Fluorouracil 88-92 epidermal growth factor receptor Homo sapiens 0-4 34589581-10 2021 Finally, in vitro and in vivo xenograft experiments consistently demonstrated that inhibition of EGFR by the specific inhibitor erlotinib effectively enhanced the anti-tumor toxicity of 5-Fu by targeting the EGFR-FGD5-AS1-miR-330-3p-HK2 pathway. Fluorouracil 186-190 epidermal growth factor receptor Homo sapiens 97-101 34097885-0 2021 Tumor-specific delivery of 5FU-incorporated EGFR-targeted aptamers as an efficient treatment in pancreatic ductal adenocarcinoma models. Fluorouracil 27-30 epidermal growth factor receptor Homo sapiens 44-48 34097885-4 2021 METHODS: We designed, generated and characterized 5FU-incorporated SELEX-selected EGFR-targeted aptamers for tumor-specific delivery of 5FU to PDAC cells and tested their therapeutic efficacy in vitro and in vivo. Fluorouracil 50-53 epidermal growth factor receptor Homo sapiens 82-86 34097885-4 2021 METHODS: We designed, generated and characterized 5FU-incorporated SELEX-selected EGFR-targeted aptamers for tumor-specific delivery of 5FU to PDAC cells and tested their therapeutic efficacy in vitro and in vivo. Fluorouracil 136-139 epidermal growth factor receptor Homo sapiens 82-86 34097885-9 2021 Tumor growth was significantly attenuated during 5FU-EGFR-aptamer treatment in the course of follow-up. Fluorouracil 49-52 epidermal growth factor receptor Homo sapiens 53-57 34589581-0 2021 Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis. Fluorouracil 26-30 epidermal growth factor receptor Homo sapiens 10-14 34589581-4 2021 Here we report that EGFR and lncRNA-FGD5-AS1 promoted 5-Fu resistance of CRC. Fluorouracil 54-58 epidermal growth factor receptor Homo sapiens 20-24 34589581-5 2021 By establishing the 5-Fu-resistant CRC cell line, we detected that EGFR, FGD5-AS1, and glucose metabolism were significantly elevated in 5-Fu-resistant CRC cells. Fluorouracil 20-24 epidermal growth factor receptor Homo sapiens 67-71 34589581-5 2021 By establishing the 5-Fu-resistant CRC cell line, we detected that EGFR, FGD5-AS1, and glucose metabolism were significantly elevated in 5-Fu-resistant CRC cells. Fluorouracil 137-141 epidermal growth factor receptor Homo sapiens 67-71 34589581-10 2021 Finally, in vitro and in vivo xenograft experiments consistently demonstrated that inhibition of EGFR by the specific inhibitor erlotinib effectively enhanced the anti-tumor toxicity of 5-Fu by targeting the EGFR-FGD5-AS1-miR-330-3p-HK2 pathway. Fluorouracil 186-190 epidermal growth factor receptor Homo sapiens 208-212 34589581-11 2021 In summary, this study demonstrates new mechanisms of the EGFR-modulated 5-Fu resistance through modulating the noncoding RNA network, contributing to development of new approaches against chemoresistant CRC. Fluorouracil 73-77 epidermal growth factor receptor Homo sapiens 58-62 33349222-11 2021 The optimized formulation (5-FU-PLGA-PEG-NP) was lyophilized using 4% trehalose (cryoprotectants) & conjugated with Anti-EGFR mAb on its surface to produce Anti-EGFR-5-FU-PLGA-PEG-NP; the final formulation, which increases target specificity and drug delivery system of nanoparticles. Fluorouracil 27-31 epidermal growth factor receptor Homo sapiens 121-125 35241559-2 2022 Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). Fluorouracil 188-202 epidermal growth factor receptor Homo sapiens 47-79 35241559-2 2022 Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). Fluorouracil 188-202 epidermal growth factor receptor Homo sapiens 81-85 33951601-10 2021 The induction of PD-L1 by 5-FU was partially prevented by Epidermal Growth Factor Receptor (EGFR) inhibition with cetuximab. Fluorouracil 26-30 epidermal growth factor receptor Homo sapiens 58-90 33951601-10 2021 The induction of PD-L1 by 5-FU was partially prevented by Epidermal Growth Factor Receptor (EGFR) inhibition with cetuximab. Fluorouracil 26-30 epidermal growth factor receptor Homo sapiens 92-96 33538278-6 2021 Furthermore, delivery of 5-FU by using this nanoplatform can remarkably induce cytotoxicity, cell cycle arrest, and cell apoptosis for CRC cells with high EGFR expression. Fluorouracil 25-29 epidermal growth factor receptor Homo sapiens 155-159 33408498-1 2020 Aim: The change in the levels of peripheral inflammatory markers together with EGFR in relation to 5- fluorouracil (5-FU) therapy was evaluated for their prognostic significance in colorectal cancer (CRC) patients. Fluorouracil 99-114 epidermal growth factor receptor Homo sapiens 79-83 33408498-1 2020 Aim: The change in the levels of peripheral inflammatory markers together with EGFR in relation to 5- fluorouracil (5-FU) therapy was evaluated for their prognostic significance in colorectal cancer (CRC) patients. Fluorouracil 116-120 epidermal growth factor receptor Homo sapiens 79-83 35326562-1 2022 The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). Fluorouracil 121-135 epidermal growth factor receptor Homo sapiens 224-228 34026617-2 2021 In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatment with cisplatin, 5-fluorouracil, and docetaxel/paclitaxel, including DNA/RNA damage repair, drug efflux, apoptosis inhibition, and epidermal growth factor receptor/focal adhesion kinase/nuclear factor-kappaB activation. Fluorouracil 135-149 epidermal growth factor receptor Homo sapiens 249-281 33349222-15 2021 Therefore, Anti-EGFR-5-FU-PLGA-PEG-NP holds excellent potential for drug delivery to EGFR positive colorectal cancer cells. Fluorouracil 21-25 epidermal growth factor receptor Homo sapiens 16-20 31959339-1 2020 BACKGROUND: Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in advanced colorectal or squamous cell head and neck cancers. Fluorouracil 110-124 epidermal growth factor receptor Homo sapiens 140-172 32742490-0 2020 Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer. Fluorouracil 50-54 epidermal growth factor receptor Homo sapiens 28-32 31837576-4 2020 Adding the epidermal growth factor receptor (EGFR) inhibitor cetuximab to a platinum/5-fluorouracil doublet (the so-called EXTREME regimen) produced a statistically but also clinically significant improvement of survival and became thus the standard first-line palliative treatment in adequately fit patients. Fluorouracil 85-99 epidermal growth factor receptor Homo sapiens 11-43 32043796-14 2020 IMPLICATIONS FOR PRACTICE: For RAS/RAF wild-type metastatic colorectal cancer, patients may receive 5-fluorouracil-based chemotherapy plus either bevacizumab or an anti-epidermal growth factor receptor (EGFR). Fluorouracil 100-114 epidermal growth factor receptor Homo sapiens 203-207 31840981-2 2020 Here, a fusion protein was designed with both an antiepidermal growth factor receptor (EGFR) affibody and the prodrug enzyme cytosine deaminase, which can convert prodrug 5-fluorocytosine to the anticancer drug 5-fluorouracil. Fluorouracil 211-225 epidermal growth factor receptor Homo sapiens 87-91 31947551-0 2020 Anti-EGFR-Coated Gold Nanoparticles In Vitro Carry 5-Fluorouracil to Colorectal Cancer Cells. Fluorouracil 51-65 epidermal growth factor receptor Homo sapiens 5-9 31947551-2 2020 5-FU was loaded on gold nanoparticles (AuNP) coated with anti-EGFR antibodies in order to target them towards colorectal cancer cells that overexpress epidermal growth factor receptors (EGFR). Fluorouracil 0-4 epidermal growth factor receptor Homo sapiens 62-66 31947551-2 2020 5-FU was loaded on gold nanoparticles (AuNP) coated with anti-EGFR antibodies in order to target them towards colorectal cancer cells that overexpress epidermal growth factor receptors (EGFR). Fluorouracil 0-4 epidermal growth factor receptor Homo sapiens 151-184 31947551-2 2020 5-FU was loaded on gold nanoparticles (AuNP) coated with anti-EGFR antibodies in order to target them towards colorectal cancer cells that overexpress epidermal growth factor receptors (EGFR). Fluorouracil 0-4 epidermal growth factor receptor Homo sapiens 186-190 30825616-12 2019 GENERAL SIGNIFICANCE: The cytotoxic activity of Pd(II) complex and 5-FU on HeLa cells is mediated by EGFR inhibition and autophagy induction, leading to activation of mitochondrial apoptotic cell death. Fluorouracil 67-71 epidermal growth factor receptor Homo sapiens 101-105 31696188-0 2019 Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic Ag2S quantum dots. Fluorouracil 121-124 epidermal growth factor receptor Homo sapiens 65-69 31696188-6 2019 Interestingly, while treatment of cells with free 5FU activated autophagy, a cellular mechanism conferring resistance to cell death, these EGFR targeting multimodal QDs significantly overcame drug resistance compared to 5FU treatment alone. Fluorouracil 50-53 epidermal growth factor receptor Homo sapiens 139-143 31696188-6 2019 Interestingly, while treatment of cells with free 5FU activated autophagy, a cellular mechanism conferring resistance to cell death, these EGFR targeting multimodal QDs significantly overcame drug resistance compared to 5FU treatment alone. Fluorouracil 220-223 epidermal growth factor receptor Homo sapiens 139-143 31488078-6 2019 Selectively, the effect of EGF receptor inhibition was augmented by a combination with 5-fluorouracil and oxaliplatin. Fluorouracil 87-101 epidermal growth factor receptor Homo sapiens 27-39 31189612-0 2019 Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. Fluorouracil 23-37 epidermal growth factor receptor Homo sapiens 95-99 31189612-6 2019 Mechanistically, vorinostat reverted 5FU/CDDP-induced EGFR phosphorylation and nuclear translocation, leading to the impairment of nuclear EGFR noncanonical induction of genes such as thymidylate synthase and cyclin D1. Fluorouracil 37-40 epidermal growth factor receptor Homo sapiens 54-58 31346466-1 2019 Background: The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). Fluorouracil 228-242 epidermal growth factor receptor Homo sapiens 16-48 31346466-1 2019 Background: The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). Fluorouracil 228-242 epidermal growth factor receptor Homo sapiens 50-54 30825616-3 2019 This study aimed to investigate whether EGFR inhibition by canertinib induces autophagy and this induction influence the effect of Palladium (Pd) (II) complex and 5-fluorouracil (5-FU) especially in nontoxic doses. Fluorouracil 163-177 epidermal growth factor receptor Homo sapiens 40-44 30825616-3 2019 This study aimed to investigate whether EGFR inhibition by canertinib induces autophagy and this induction influence the effect of Palladium (Pd) (II) complex and 5-fluorouracil (5-FU) especially in nontoxic doses. Fluorouracil 179-183 epidermal growth factor receptor Homo sapiens 40-44 30825616-7 2019 RESULTS: Blocking EGFR by the pan-ErbB tyrosine kinase inhibitor canertinib inhibited cell growth of HeLa cervical cancer cells in combination with Pd(II) complex and 5-FU. Fluorouracil 167-171 epidermal growth factor receptor Homo sapiens 18-22 31896739-0 2020 Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer. Fluorouracil 57-61 epidermal growth factor receptor Homo sapiens 19-23 31896739-8 2020 The regulatory role of EGFR in 5-FU resistance was validated in colon cancer cells in vivo and in vitro. Fluorouracil 31-35 epidermal growth factor receptor Homo sapiens 23-27 31896739-9 2020 EGFR contributed to 5-FU resistance in colon cancer cells through autophagy induction, and EGFR overexpression in 5-FU resistant colon cancer was regulated by RARA. Fluorouracil 20-24 epidermal growth factor receptor Homo sapiens 0-4 31896739-9 2020 EGFR contributed to 5-FU resistance in colon cancer cells through autophagy induction, and EGFR overexpression in 5-FU resistant colon cancer was regulated by RARA. Fluorouracil 114-118 epidermal growth factor receptor Homo sapiens 91-95 29864476-0 2018 Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. Fluorouracil 103-107 epidermal growth factor receptor Homo sapiens 68-72 30662270-0 2019 Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report. Fluorouracil 23-35 epidermal growth factor receptor Homo sapiens 72-76 30662270-9 2019 Conclusion: The combination of fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor may have synergistic action, leading to recession of secondary metastases in patients with BRAFV600E-mutated colorectal cancer. Fluorouracil 31-43 epidermal growth factor receptor Homo sapiens 80-84 30056083-3 2018 Compared to 5-FU alone, MH synergistically enhanced the chemotherapeutic effects of 5-FU, by reducing cell proliferation through the suppression of EGFR, HER2, p-Akt and p-mTOR expression, and promoting apoptosis by the modulation pro-apoptotic (p53, Bax, Cyto c, FasL caspase-3, -8, -9 and cleave-PARP) and anti-apoptotic (Bcl-2) markers. Fluorouracil 84-88 epidermal growth factor receptor Homo sapiens 148-152 29864476-3 2018 In this work, an EGFR-targeted immunoliposome loaded with 5-fluorouracil (5- FU) was developed to allow co-administration of the antibody and the chemotherapeutic agent and selective delivery to SCC cells. Fluorouracil 58-72 epidermal growth factor receptor Homo sapiens 17-21 29864476-3 2018 In this work, an EGFR-targeted immunoliposome loaded with 5-fluorouracil (5- FU) was developed to allow co-administration of the antibody and the chemotherapeutic agent and selective delivery to SCC cells. Fluorouracil 74-79 epidermal growth factor receptor Homo sapiens 17-21 29480364-4 2018 The effect of radiation, 5-fluorouracil (5-Fu), and gefitinib on the EGFR, AKT, and ERK1/2 activation in H1975 cells was determined by Western blot. Fluorouracil 41-45 epidermal growth factor receptor Homo sapiens 69-73 29086459-11 2018 In humans, the expression of EGFR is increased in patients with colorectal cancer treated with 5-FU compared with cancer patients not on 5-FU. Fluorouracil 95-99 epidermal growth factor receptor Homo sapiens 29-33 29086459-11 2018 In humans, the expression of EGFR is increased in patients with colorectal cancer treated with 5-FU compared with cancer patients not on 5-FU. Fluorouracil 137-141 epidermal growth factor receptor Homo sapiens 29-33